Peptide inhibitors of β-amyloid aggregation

Current Opinion in Drug Discovery and Development

Volumn 10, Issue 5, 2007, Pages 533-539

  Doig, A J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Sheet; Alzheimer's disease; Drug; Fibril; Peptidomimetic

Indexed keywords

4' IODOESORUBICIN; AMYLOID BETA PROTEIN; ANTHRACYCLINE; BETA CYCLODEXTRIN; CHOLINESTERASE INHIBITOR; CHOLYL LEUCYLVALYLPHENYLALANYLPHENYLALANYLALANYL; COLLAGEN TYPE 4; DAUNORUBICIN; DEXTRO[(METHYLLEUCINE)VALYLPHENYLALANYLPHENYLALANYLLEUCYL]AMIDE; DEXTRO[[R CYCLOHEXYLGLYCINE]Y(R CYCLOHEXYLGLYCINE)(R CYCLOHEXYLGLYCINE)[N METHYLLEUCINE]]AMIDE; DONEPEZIL; GLYCOSAMINOGLYCAN; GLYCYLVALYLVALYLISOLEUCYLALANYL AMIDE; LEUCYLPROLYLPHENYLALANYLPHENYLALANYLASPARTYL; LYSYLLEUCYLVALYLPHENYLALANYLPHENYLALANYL; LYSYLLEUCYLVALYLPHENYLALANYLPHENYLALANYLGLUTAMYLGLUTAMYLGLUTAMYLGLUTAMYL; LYSYLLEUCYLVALYLPHENYLALANYLPHENYLALANYLLYSYLLYSYLLYSYLLYSYL; LYSYLLEUCYLVALYLPHENYLALANYLPHENYLALANYLLYSYLLYSYLLYSYLLYSYLLYSYLLYSYL; LYSYLLEUCYLVALYLPHENYLALANYLPHENYLALANYLSERYLSERYLSERYLSERYL; MELATONIN; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PENTAPEPTIDE; PEPTIDE INHIBITOR; PORPHYRIN; PPI 1019; PPI 368; PROTEIN INHIBITOR; RIFAMPICIN; SEN 304; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALYLGLYCYLGLYCYLVALYLVALYL;

ALZHEIMER DISEASE; DRUG MECHANISM; HUMAN; IMMUNIZATION; METHYLATION; PROTEIN AGGREGATION; REVIEW; TOXICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; DRUG DESIGN; HUMANS; PEPTIDES; PROTEIN CONFORMATION;

EID: 34548410504     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Dobson CM: Protein misfolding, evolution and disease. Trends Biochem Sci (1999) 24(9):329-332.
2. Holtzman DM, Mobley WC: Molecular studies in Alzheimer's disease. Trends Biochem Sci (1991) 16(4):140-144.
3. Selkoe DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature (1999) 399(6738 Suppl):A23-A31.
4. Robinson S, Bishop GM: Aβ as a bioflocculant: Implications for the amyloid hypothesis of Alzheimer's disease. Neurobiol Aging (2002) 23(6):1051-1072.
5. Klein WL, Krafft GA, Finch CE: Targeting small Aβ oligomers: The solution to an Alzheimer's disease conundrum?Trends Neurosci (2001) 24(4):219-224.
6. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P et al: Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Nat Acad Sci USA (1998) 95(11):6448-6453.
7. Lesné S, Kosh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH: A specific amyloid-β protein assembly in the brain impairs memory. Nature (2006) 440(7082):352-357. •• Identification of Aβ dodecamers as the primary toxic species in transgenic mice.
8. Haass C, Selkoe DJ: Soluble protein oligomers in neurondegeneration: Lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol (2007) 8(2):101-112.
9. Walsh DM, Selkoe DJ: Aβ oligomers - a decade of discovery. J Neurochem (2007) 101(5):1172-1184. • Highly readable review of current thinking on the importance of Aβ oligomers.
10. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, Roebroek AJ et al: Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem (2005) 280(35):30797-30806.
11. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C: Control of peripheral nerve myelination by the β-secretase BACE1. Science (2006) 314(5799):664-666. •• BACE1 is demonstrated to be involved with myelination and correct bundling of axons by Schwann cells, suggesting that its inhibition may not be a good strategy for the treatment of AD.
12. Parks AL, Curtis D: Presenilin diversifies its portfolio. Trends Genet (2007) 23(3):140-150.
13. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D et al: Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400(6740):173-177. •• This study demonstrates that vaccination with Aβ can prevent AD pathology in a transgenic mouse.
14. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO: Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: A case report. Nat Med (2003) 9(4):448-452. • Results of Aβ vaccination in a human trial.
15. McGeer PL, McGeer EG: NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neurobiol Aging (2007) 28(5):639-647.
16. Chauhan V, Chauhan A: Oxidative stress in Alzheimer's disease. Pathophysiology (2006) 13(3):195-208.
17. Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, Kagan B, Ghiso J, Lal R: Amyloid ion channels: A common structural link for protein-misfolding disease. Proc Nat Acad Sci USA (2005) 102(30):10427-10432. •• Ion channel formation is demonstrated to be associated with a wide range of amyloidogenic peptides and proteins.
18. Bush AI: Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging (2002) 23(6):1031-1038.
19. Lansbury PT: Inhibition of amyloid formation: A strategy to delay the onset of Alzheimer's disease. Curr Opin Chem Biol (1997) 1(2):260-267.
20. Salomon AR, Marcinowski KJ, Friedland RP, Zagorski MG: Nicotine inhibits amyloid formation by the β-peptide. Biochemistry (1996) 35(42):13568-13578.
21. Moore SA, Huckerby TN, Gibson GL, Fullwood NJ, Turnbull S, Tabner BJ, El-Agnaf OM, Allsop D: Both the D-(+) and L-(-) enantiomers of nicotine inhibit Aβ aggregation and cytotoxicity. Biochemistry (2004) 43(3):819-826.
22. Camilleri P, Haskins NJ, Howlett DR: β-Cyclodextrin interacts with the Alzheimer amyloid β-A4 peptide. FEBS Lett (1994) 341(2-3):256-258.
23. Howlett D, Cutler P, Heales S, Camilleri P: Hemin and related porphyrins inhibit β-amyloid aggregation. FEBS Lett (1997) 417(2):249-251.
24. Merlini G, Ascari E, Amboldi N, Belloti V, Arbustini E, Perfetti V, Ferrari M, Zorzoli I, Marinone MG, Garini P, Diegoli M et al: Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis. Proc Nat Acad Sci USA (1995) 92(7):2959-2963.
25. Wood SJ, MacKenzie L, Maleef B, Hurle MR, Wetzel R: Selective inhibition of Aβ fibril formation. J Biol Chem (1996) 271(8):4086-4092.
26. Tomiyama T, Shoji A, Kataoka K, Suwa Y, Asano S, Kaneko H, Endo N: Inhibition of amyloid β protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J Biol Chem (1996) 271(12):6839-6844.
27. Parker MH, Chen R, Conway KA, Lee DH, Luo C, Boyd RE, Nortey SO, Ross TM, Scott MK, Reitz AB: Synthesis of (-)-5,8-dihydroxy-3R-methyl-2R- (dipropylamino)-1,2,3,4-tetrahydronaphthalene: An inhibitor of β-amyloid(1-42) aggregation. Bioorg Med Chem (2002) 10(11):3565-3569.
28. Kiuchi Y, Isobe Y, Fukushima K: Type IV collagen prevents amyloid β-protein fibril formation. Life Sci (2002) 70(13):1555- 1564.
29. Pappolla M, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, Frangione B, Ghiso J: Inhibition of Alzheimer β-fibrillogenesis by melatonin. J Biol Chem (1998) 273(13):7185-7188.
30. Howlett DR, George AR, Owen DE, Ward RV, Markwell RE: Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer β-amyloid fibril formation. Biochem J (1999) 343(Pt 2):419-423.
31. McLaurin J, Franklin T, Zhang X, Deng J, Fraser PE: Interactions of Alzheimer amyloid-β peptides with glycosaminoglycans effects on fibril nucleation and growth. Eur J Biochem (1999) 266(3):1101-1110.
32. Kim JE, Lee M: Fullerene inhibits β-amyloid peptide aggregation. Biochem Biophys Res Commun (2003) 303(2):576-579.
33. Lashuel HA, Hartley DM, Balakhaneh D, Aggarwal A, Teichberg S, Callaway DJ: New class of inhibitors of amyloid-β fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. J Biol Chem (2002) 277(45):42881-42890.
34. Bendheim PE, Poeggeler B, Neria E, Ziv V, Pappolla MA, Chain DG: Development of indole-3-propionic acid (OXIGON) for Alzheimer's disease. J Mol Neurosci (2002) 19(1):213-217.
35. Matsuzaki K, Noguch T, Wakabayashi M, Ikeda K, Okada T, Ohashi Y, Hoshino M, Naiki H: Inhibitors of amyloid β-protein aggregation mediated by GM1-containing raft-like membranes. Biochim Biophys Acta (2007) 1768(1):122-130.
36. Lin SJ, Shiao YJ, Chi CW, Yang LM: Aβ aggregation inhibitors. Part 1: Synthesis and biological activity of phenylazo benzene-sulfonamides. Bioorg Med Chem Lett (2004) 14(5):1173-1176.
37. Wang SS, Chen YT, Chou SW: Inhibition of amyloid fibril formation of β-amyloid peptides via the amphiphilic surfactants. Biochim Biophys Acta (2005) 1741(3):307-331.
38. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM: Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem (2005) 280(7):5892-5901. • The spice curcumin is an effective inhibitor of Aβ toxicity in vitro and in vivo.
39. Rzepecki P, Nagel-Steger L, Feuerstein S, Linne U, Molt O, Zadmard R, Aschermann K, Wehner M, Schrader T, Riesner D: Prevention of Alzheimer's disease-associated Aβ aggregation by rationally designed nonpeptidic β-sheet ligands. J Biol Chem (2004) 279(46): 47497-47505. • Inhibitors can be designed to maintain the hydrogen-bonding pattern present in β-sheets.
40. McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE: Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid β peptide and inhibit Aβ induced toxicity. J Biol Chem (2000) 275(24):18495-18502.
41. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen F et al: Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med (2006) 12(7):801-808.
42. Porat Y, Abramowitz A, Gazit E: Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des (2006) 67(1):27-37.
43. Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D: A phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease. Neurology (2006) 67(10):1757-1763.
44. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, Lacombe D, Kong X, Aman A, Laurin J, Szarek WA et al: Targeting soluble Aβ peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging (2007) 28(4):537-547.
45. Tang NK, Zhang JT: Salvianolic acid B inhibits fibril formation and neurotoxicity of amyloid β-protein in vitro. Acta Pharmacol Sin (2001) 22(4):380-384.
46. Eubanks LM, Rogers CJ, Beuscher AE, Koob GF, Olson AJ, Dickerson TJ, Janda KD: A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm (2006) 3(6):773-777.
47. Gestwicki JE, Crabtree GR, Graef IA: Harnessing chaperones to generate small-molecule inhibitors of amyloid β aggregation. Science (2004) 306(5697):865-869.
48. Tjernberg LO, Näslund J, Lindqvist F, Johansson J, Karlström AR, Thyberg J, Terenius L, Nordstedt C: Arrest of β-amyloid fibril formation by a pentapeptide ligand. J Biol Chem (1996) 271(15): 8545-8548. • Identification of KLVFF as the key amyloidogenic domain of Aβ - the core of most peptide inhibitors of Aβ aggregation.
49. Tjernberg LO, Lilliehöök C, Callaway DJ, Näslund J, Hahne S, Thyberg J, Terenius L, Nordstedt C: Controlling amyloid β-peptide fibril formation with protease-stable ligands. J Biol Chem (1997) 272(19):12601-12605.
50. Matsunaga Y, Fujii A, Awasthi A, Yokotani J, Takakura T, Yamada T: Eight-residue Aβ peptides inhibit the aggregation and enzymatic activity of Aβ42. Regul Pept (2004) 120(1-3):227-236.